Press release
Neuroendocrine tumors Pipeline Analysis, 2025 by DelveInsight | RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp
Neuroendocrine tumors Pipeline Analysis
DelveInsight reports that the Neuroendocrine Tumors (NET) pipeline involves over 100 key companies actively developing more than 120 therapeutic candidates.
Neuroendocrine tumors Overview:
Neuroendocrine cancer, also called a neuroendocrine tumor (NET) or neuroendocrine neoplasm, arises from specialized cells of the neuroendocrine system, which exhibit traits of both hormone-secreting endocrine cells and nerve cells. These cells are found throughout the body and play a vital role in regulating various physiological processes. Hormones produced by these cells act as chemical messengers, traveling through the bloodstream to affect the function of organs or cells. NETs typically grow slowly, often taking years to develop.
NETs are categorized as functional or nonfunctional depending on their hormone secretion. Functional NETs produce excess hormones, whereas nonfunctional NETs either secrete none or produce amounts too low to trigger noticeable symptoms. The specific hormone produced depends on the tumor's location in the body. According to the American Society of Clinical Oncology (ASCO), roughly 60% of NETs are nonfunctional. Whether a NET is functional significantly affects both the symptoms experienced and the treatment strategy.
NETs are often discovered for various reasons since they usually do not cause a consistent set of symptoms. In early stages, they are often asymptomatic and may be found incidentally during imaging or surgery for unrelated conditions. When symptoms do appear, they are typically related to the tumor's size, location, or hormone production, as seen in cases such as carcinoid syndrome.
Download our report @ https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Neuroendocrine tumors Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Neuroendocrine tumors Therapeutics Market.
Key Takeaways from the Neuroendocrine tumors Pipeline Report
*
DelveInsight's report on the Neuroendocrine Tumors (NET) pipeline highlights a vibrant landscape, with over 100 companies actively developing more than 120 therapeutic candidates for NET treatment.
*
In December 2024, the FDA approved CRENESSITY Trademark (crinecerfont) from Neurocrine Biosciences for the treatment of classic congenital adrenal hyperplasia (CAH). While CAH is not a neuroendocrine tumor, this milestone underscores continued progress in endocrine-related therapies.
*
Leading companies advancing NET treatments include RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, and others.
*
Notable NET pipeline therapies in various stages of development include RYZ101, CAM2029, Ramucirumab, Voyager-V1, ADCT-701, among several additional candidates.
Neuroendocrine tumors Pipeline Analysis
The Neuroendocrine tumors pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Neuroendocrine tumors Market.
*
Categorizes Neuroendocrine tumors therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Neuroendocrine tumors drugs under development based on:
*
Stage of development
*
Neuroendocrine tumors Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Neuroendocrine tumors Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Neuroendocrine tumors Licensing agreements
*
Funding and investment activities supporting future Neuroendocrine tumors market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Neuroendocrine tumors Emerging Drugs
*
RYZ101: RayzeBio, Inc.
*
CAM2029: Camurus
*
Ramucirumab: Eli Lilly and Company
*
Voyager-V1: Vyriad, Inc.
*
ADCT-701: ADC Therapeutics
Neuroendocrine tumors Companies
More than 100 leading companies are actively developing therapies for neuroendocrine tumors, with RayzeBio, Inc. advancing a drug candidate to the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 120+ products under different phases of Neuroendocrine tumors clinical trials like
*
Neuroendocrine tumors Late stage Therapies (Phase III)
*
Neuroendocrine tumors Mid-stage Therapies (Phase II)
*
Neuroendocrine tumors Early-stage Therapies (Phase I)
*
Neuroendocrine tumors Pre-clinical and Neuroendocrine tumors Discovery stage Therapies
*
Neuroendocrine tumors Discontinued & Inactive Therapies
Neuroendocrine tumors pipeline report provides the Neuroendocrine tumors therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Neuroendocrine tumors Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Neuroendocrine tumors Therapies and Key Neuroendocrine tumors Companies: Neuroendocrine tumors Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Neuroendocrine tumors Pipeline Therapeutic Assessment
- Neuroendocrine tumors Assessment by Product Type
- Neuroendocrine tumors By Stage
- Neuroendocrine tumors Assessment by Route of Administration
- Neuroendocrine tumors Assessment by Molecule Type
Download Neuroendocrine tumors Sample report to know in detail about the Neuroendocrine tumors treatment market @ Neuroendocrine tumors Therapeutic Assessment [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Neuroendocrine tumors Current Treatment Patterns
4. Neuroendocrine tumors - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Neuroendocrine tumors Late-Stage Products (Phase-III)
7. Neuroendocrine tumors Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuroendocrine tumors Discontinued Products
13. Neuroendocrine tumors Product Profiles
14. Neuroendocrine tumors Key Companies
15. Neuroendocrine tumors Key Products
16. Dormant and Discontinued Products
17. Neuroendocrine tumors Unmet Needs
18. Neuroendocrine tumors Future Perspectives
19. Neuroendocrine tumors Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Neuroendocrine tumors Pipeline Reports Offerings [https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroendocrine-tumors-pipeline-analysis-2025-by-delveinsight-rayzebio-inc-camurus-vyriad-inc-adc-therapeutics-eli-lilly-and-company-biotheus-inc-immunitybio-inc-chimerix-merck-sharp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroendocrine tumors Pipeline Analysis, 2025 by DelveInsight | RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp here
News-ID: 4165683 • Views: …
More Releases from ABNewswire
Natural Killer Cell Therapies Pipeline Analysis 2025 by DelveInsight | ImmunityB …
DelveInsight's, "Natural Killer Cell Therapies - Pipeline Insight, 2025," report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Natural Killer…
Non-Alcoholic Fatty Liver Disease Pipeline Analysis 2025 by DelveInsight | Guang …
DelveInsight's, "Non-Alcoholic Fatty Liver Disease - Pipeline Insight, 2025" report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Non-Alcoholic Fatty…
Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis, 2025 by DelveInsight | Mer …
DelveInsight's, Non-Small-Cell Lung cancer (NSCLC) - Pipeline Insight, 2025," report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Non-Small-Cell Lung…
IBN Technologies' Professional Bookkeeping Services Give U.S. Hoteliers Financia …
IBN Technologies offers tailored bookkeeping services for U.S. hoteliers, including resorts and restaurants. With cloud-based solutions for tip tracking, payroll, expense segregation, and multi-departmental reconciliation, businesses gain clarity, reduce errors, and streamline financial reporting-ensuring compliance and supporting growth.
Miami, Florida, 01 Sep 2025 The high turnover environment in which hotels, resorts, and food service businesses operate across the United States necessitates careful financial coordination. There is less opportunity for financial errors…
More Releases for Neuroendocrine
Neuroendocrine Carcinoma Market Massive Growth opportunity Ahead
Introduction
Neuroendocrine carcinoma (NEC) is a rare and aggressive form of cancer that arises from neuroendocrine cells, which are found throughout the body and are responsible for producing hormones. These tumors can occur in various organs, including the lungs, pancreas, liver, and gastrointestinal tract. Due to its often vague and non-specific symptoms, neuroendocrine carcinoma is frequently diagnosed at an advanced stage, making it challenging to treat effectively.
In recent years, however, there…
Rising Neuroendocrine Tumors Fuel Treatment Market Growth Driving Market Acceler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Neuroendocrine Tumor Treatment Market Size By 2025?
The industry for treating neuroendocrine tumors has witnessed substantial growth in the previous years. The market size is projected to escalate from $2.17 billion in 2024 to $2.4 billion in 2025, with a compound annual growth rate (CAGR)…
Emerging Trends Influencing The Growth Of The Neuroendocrine Tumor Treatment Mar …
The Neuroendocrine Tumor Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Neuroendocrine Tumor Treatment Market Size Expected to Be by 2034?
The market for neuroendocrine tumor treatment has seen a significant expansion in recent years. Projected to grow from a value…
Prominent Neuroendocrine Tumor Treatment Market Trend for 2025: Clinical Trials …
How Are the key drivers contributing to the expansion of the neuroendocrine tumor treatment market?
The neuroendocrine tumor treatment market is forecasted to expand due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, or NETs, are rare growths that begin in neuroendocrine cells, and their treatment is vital to managing the symptoms, controlling the tumor's growth, and applying radiation therapy to destroy the cancerous cells. The American Society of Clinical…
Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise…
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.
Neuroendocrine Cancer Market Segmentation Analysis
Total Neuroendocrine Cancer Studies: 2499
By Drug Type
Everolimus
Sunitinib Malate
Lanreotide
Octreotide
Others
Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of…
